Daraxonrasib Nearly Doubles Pancreatic Cancer Survival to 13.2 Months in Phase 3 Trial
Updated
Updated · USA TODAY · Jun 8
Daraxonrasib Nearly Doubles Pancreatic Cancer Survival to 13.2 Months in Phase 3 Trial
3 articles · Updated · USA TODAY · Jun 8
Summary
13.2 months of median survival was achieved by metastatic pancreatic cancer patients on daraxonrasib, versus 6.7 months with chemotherapy in a phase 3 trial published in the New England Journal of Medicine.
60% lower risk of death was linked to the daily oral drug, which targets mutated RAS proteins that drive uncontrolled tumor growth and have long been difficult to drug.
April 30 brought FDA clearance for an early-access program for some patients, while formal approval could come later in 2026 if no major setbacks emerge.
52,740 Americans are expected to die from pancreatic cancer this year, underscoring why researchers called the result a potential paradigm shift for one of the deadliest cancers.
A new pill doubles survival for a deadly cancer, but will its eventual price put it out of reach?
This breakthrough drug targets a common mutation. Could it be the key to treating many other major cancers?
As this drug defeats cancer cells, for how long can it work before the cancer adapts and resists?
Daraxonrasib Nearly Doubles Survival in Metastatic Pancreatic Cancer: RASolute 302 Trial Ushers in New Era of Targeted Therapy
Overview
The phase III RASolute 302 trial, presented by Brian M. Wol at the 2026 ASCO Annual Meeting, marked a pivotal moment for patients with previously treated metastatic pancreatic cancer. The trial showcased the remarkable efficacy of daraxonrasib, a multiselective RAS(ON) inhibitor, leading to unprecedented improvements in patient outcomes. Notably, the median overall survival nearly doubled, and patients experienced substantial gains in progression-free survival. These results signal a game-changing advancement in oncology, offering new hope for a challenging patient population and reshaping expectations for cancer treatment.